NCT00469378View on ClinicalTrials.gov

Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

February 28, 2010

Conditions
Multiple Sclerosis
Interventions
DRUG

firategrast

900 (females) or 1200 (males) mg twice daily for 24 weeks

Trial Locations (10)

1070

GSK Investigational Site, Brussels

1200

GSK Investigational Site, Brussels

1478

GSK Investigational Site, Lørenskog

2100

GSK Investigational Site, Koebenhavn Ø

775 20

GSK Investigational Site, Olomouc

120 00

GSK Investigational Site, Prague

DK-2600

GSK Investigational Site, Glostrup Municipality

SE-416 85

GSK Investigational Site, Gothenburg

SE-171 76

GSK Investigational Site, Stockholm

SE-901 85

GSK Investigational Site, Umeå

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY